Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genitope Maintains Positive View On MyVax Despite DSMB Interim Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Data safety monitoring board recommends Genitope continue a Phase III trial of the cancer vaccine, suggesting more data is needed.

You may also be interested in...



Genitope Encouraged By Positive Progression-Free Survival “Trend” In Phase III MyVax Trial

Final data on the personalized cancer vaccine’s use in non-Hodgkin’s lymphoma are expected in November.

Genitope Encouraged By Positive Progression-Free Survival “Trend” In Phase III MyVax Trial

Final data on the personalized cancer vaccine’s use in non-Hodgkin’s lymphoma are expected in November.

Cancer Vaccine Maker Therion Is Up For Sale After Disappointing Phase III Results

Therion no longer plans to submit a BLA for its PANVAC-VF pancreatic cancer treatment.

Topics

UsernamePublicRestriction

Register

PS064688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel